Related Experiment Video
Updated: Dec 10, 2025
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Dual targeting of NUAK1 and ULK1 using the multitargeted inhibitor MRT68921 exerts potent antitumor activities
Yiran Chen1, Xiaoling Xie1, Chunsheng Wang1
1Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
Abstract:
Utilizing oxidative stress has recently been regarded as a potential strategy for tumor therapy. The NUAK family SNF1-like kinase 1 (NUAK1) is a critical component of the antioxidant defense system and is necessary for the survival of tumors. Therefore, NUAK1 is considered an attractive therapeutic target in cancer. However, antioxidant therapy induced elevated ROS levels to activate the Unc-51-like kinase 1 (ULK1) pathway to promote protective autophagy and ULK1-dependent mitophagy. Thus, the combined inhibition of NUAK1 and ULK1 showed a strong synergistic effect in different tumor types. Herein, the potential antitumor activities of a dual NUAK1/ULK1 inhibitor MRT68921 were evaluated in both tumor cell lines and animal models. MRT68921 significantly kills tumor cells by breaking the balance of oxidative stress signals. These results highlight the potential of MRT68921 as an effective agent for tumor therapy.
Insights
Targeting NUAK1 and ULK1 with MRT68921 shows promise for cancer therapy. This dual inhibitor disrupts oxidative stress balance, effectively killing tumor cells and highlighting its potential as an antitumor agent.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Oxidative stress is a developing strategy for tumor therapy.
- NUAK1 (NUAK family SNF1-like kinase 1) is vital for tumor survival and antioxidant defense, making it a therapeutic target.
- Antioxidant therapy can paradoxically activate protective autophagy via the ULK1 pathway, necessitating combined inhibition.
Purpose of the Study:
- To evaluate the antitumor potential of the dual NUAK1/ULK1 inhibitor MRT68921.
- To assess MRT68921's efficacy in tumor cell lines and animal models.
- To investigate MRT68921's mechanism in disrupting oxidative stress balance.
Main Methods:
- In vitro evaluation of MRT68921 in tumor cell lines.
- In vivo assessment of MRT68921 in animal models.
- Analysis of oxidative stress signaling pathways affected by MRT68921.
Main Results:
- MRT68921 demonstrated significant tumor cell killing.
- The inhibitor effectively broke the balance of oxidative stress signals in tumors.
- Combined inhibition of NUAK1 and ULK1 exhibited synergistic effects in preclinical models.
Conclusions:
- MRT68921 shows significant potential as an effective antitumor agent.
- Dual inhibition of NUAK1 and ULK1 is a promising therapeutic strategy.
- MRT68921 warrants further investigation for cancer treatment applications.
